Mural Oncology PLC (NASDAQ:MURA) Given Consensus Rating of “Hold” by Brokerages

Mural Oncology PLC (NASDAQ:MURA) has been given a consensus rating of “Hold” by the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $12.00.

MURA has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Mural Oncology in a research report on Thursday. Wall Street Zen lowered Mural Oncology from a “hold” rating to a “strong sell” rating in a research note on Sunday, August 10th.

Mural Oncology Stock Down 0.5%

NASDAQ:MURA opened at $2.09 on Friday. The business’s 50-day moving average price is $2.09 and its 200 day moving average price is $2.26. Mural Oncology has a 52-week low of $0.95 and a 52-week high of $4.74. The firm has a market cap of $36.24 million, a P/E ratio of -0.30 and a beta of 2.93.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.38. Sell-side analysts expect that Mural Oncology will post -7.54 EPS for the current year.

Institutional Trading of Mural Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Mural Oncology during the second quarter valued at approximately $192,000. Armistice Capital LLC boosted its stake in Mural Oncology by 1.3% in the 1st quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock worth $2,170,000 after purchasing an additional 22,000 shares during the period. Virtu Financial LLC purchased a new position in Mural Oncology during the 3rd quarter worth approximately $115,000. Shay Capital LLC acquired a new stake in Mural Oncology during the 3rd quarter valued at $93,000. Finally, Yakira Capital Management Inc. purchased a new stake in shares of Mural Oncology in the third quarter valued at $339,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.